Johnson & Johnson (J&J) has announced plans to separate its orthopedics business into an independent company. Operating under the DePuy Synthes name, the new entity is expected to become the world’s largest and most comprehensive orthopedics-focused firm.
The move is designed to allow J&J to concentrate on higher-growth, higher-margin areas within its MedTech and Innovative Medicine divisions. Through this spinoff, J&J expects each business to enhance revenue growth and strengthen operating performance.
The separation is anticipated to be completed within 18 to 24 months, pending regulatory, board, and employee consultation approvals. In fiscal year 2024, J&J’s orthopedics segment generated approximately $9.2 billion in sales.
Daniel Beaird is Head of Content and Editor-in-Chief of Healthcare Purchasing News (HPN), where he leads editorial strategy and content development across print, digital, podcasts, webinars, and educational programming. His coverage focuses on healthcare supply chain, sterile processing, infection prevention, and perioperative services, connecting industry developments with the purchasing and operational decisions that shape patient care.
Before joining HPN, he served as Senior Editor of The Journal of Healthcare Contracting, covering health system supply chain strategy, industry partnerships and the evolving business of healthcare.
He holds a bachelor’s degree in journalism from the University of Georgia and is based in Atlanta.